Urodynamix Technologies Ltd. 

(Public, CVE:URO)   Watch this stock   
Find more results for URO

Key stats and ratios

Q2 (Jun '09) 2008
Net profit margin -4136.36% -1814.29%
Operating margin -3922.73% -1828.04%
EBITD margin - -1804.76%
Return on average assets -193.89% -115.26%
Return on average equity -342.24% -145.67%
Employees 16 -

Address

Suite 1351 409 Granville Street
Vancouver, BC V6C 1T2
Canada
+1-604-6947770 (Phone)
+1-604-6947771 (Fax)

Website links

Urodynamix Technologies Ltd. discussions

  View all discussions »

Description

Urodynamix Technologies Ltd. is a Canadian medical device company that develops and commercializes non-invasive medical devices based on applications of near-infrared spectroscopy (NIRS) for the diagnosis of urological diseases and conditions, including urinary incontinence (UI), lower urinary tract symptoms (LUTS), prostate cancer and benign prostatic hyperplasia (BPH), erectile dysfunction (ED), and intra-abdominal hypertension (IAH) and abdominal compartment syndrome (ACS). NIRS Urodynamics (URO-NIRS) device is being developed to aid in the non-invasive painless diagnosis of diseases of the bladder during testing of patients with UI and bladder dysfunction. During the year ended December 31, 2007, it filed a patent application for NIRS Intra-abdominal Pressure Monitor (NIRS IAP) to encompass IAP monitoring applications. In October 2007, Urodynamix further expanded its NIRS clinical development program to include a new application that measures blood flow in the prostate gland.

Officers and directors

Barry J. Allen
President, Chief Executive Officer, Director
Jonathan G. E. Jackson
Chief Financial Officer
Luya Li Ph.D.
Vice President - Technology
Greg Gauthier
Vice President - Business Development
Tanner W. Philp
Corporate Secretary
Age: 37
Paul L. Geyer
Director
Age: 45
Jim Heppell
Independent Director
Zeid Mohamedali M.D.
Director
Pierre Leduc
Director
David A. Goodkin M.D.
Director
Age: 50